Article Text

PDF

Concise report
Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study
  1. Claudia S Brueckner1,
  2. Mike O Becker1,
  3. Thomas Kroencke2,
  4. Doerte Huscher3,
  5. Hans Ulrich Scherer1,
  6. Margitta Worm4,
  7. Gerd Burmester1,
  8. Gabriela Riemekasten1
  1. 1Clinic of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Germany
  2. 2Clinic of Radiology and Interventional Radiology, Charité Universitätsmedizin Berlin, Germany
  3. 3German Rheumatology Research Centre, Berlin, Germany
  4. 4Clinic of Dermatology, Venerology, and Allergology, Charité Universitätsmedizin Berlin, Germany
  1. Correspondence to Dr Gabriela Riemekasten, Clinic of Rheumatology and Clinical Immunology, Charitéplatz 1, 10117 Berlin, Germany; gabriela.Riemekasten{at}charite.de

Abstract

Objective In this pilot study, the effect of sildenafil on digital ulcer (DU) healing and related clinical symptoms was analysed.

Methods A total of 19 patients with systemic sclerosis (SSc) were treated with maximally tolerated sildenafil doses up to 6 months. Primary outcome was the healing of DUs. Changes in other clinical symptoms were also evaluated.

Results In all, 49 DUs were present at baseline; this decreased to 17 ulcers (p<0.001) at the end of sildenafil treatment. Furthermore, the visual analogue scale (VAS) score for Raynaud's phenomenon (RP), pain and activity improved (p=0.003, p=0.002 and p=0.05, respectively). A total of 9 patients developed 12 new DUs during sildenafil treatment.

Conclusions This study indicates an effect of sildenafil on DU healing in patients with SSc and an improvement of RP and associated symptoms that should be validated in controlled studies.

This paper is freely available online under the BMJ Journals unlocked scheme, see http://ard.bmj.com/info/unlocked.dtl

Statistics from Altmetric.com

Footnotes

  • Funding The study was supported by an unrestricted grant from Pfizer. Furthermore, the study was supported by the German Network for Systemic Sclerosis (DNSS) as well as by the EUSTAR network for assessment strategies.

  • Competing interests GR received lecturer's fees from Encysive, Actelion, GSK and Pfizer.

  • Ethics approval This study was conducted with the approval of the local ethical committee (Charité Berlin).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent Obtained.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.